New PHE Study Released on Cost of Nonadherence

A novel approach to measuring the cost of nonadherence is outlined in a new article by Precision experts Jason Shafrin, Ross Maclean, and colleagues. The authors report findings of an adherence-exposure-outcome model simulation on the impact of nonadherence on progression-free survival in Cancer Management and Research.

To read the complete article as it appears in the publication, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.